The report highlights market dynamics, growth drivers, key challenges, and opportunities across the region.
Meticulous Research®, a globally recognized leader in market intelligence, has released a new report titled, “Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) – Forecast to 2031.” According to the findings, the Middle East in vitro diagnostics (IVD) market is projected to reach $2.15 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.
Key Market Drivers
The growth of the Middle East IVD market is driven by several factors, including the rising prevalence of chronic and infectious diseases, increased demand for point-of-care (PoC) and rapid diagnostic solutions, expanding healthcare expenditures, and an aging population. Moreover, growing healthcare awareness, especially in countries such as the UAE and Saudi Arabia, is also contributing to market expansion. However, the high costs associated with IVD tests and inconsistencies in results from rapid diagnostic tests present challenges to sustained growth.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5764
Emerging Opportunities
Increasing awareness around early disease detection and personalized medicine, particularly in the UAE and Saudi Arabia, is creating opportunities for market players. These regions are witnessing an uptick in the adoption of advanced diagnostic technologies, which is expected to fuel demand in the coming years. Nonetheless, issues such as false positives in immunoassays and PoC tests remain significant hurdles that stakeholders need to address.
Competitive Landscape
The Middle East IVD market is dominated by global healthcare giants such as Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers AG (Germany). Other key players include QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (U.S.), and Bio-Rad Laboratories, Inc. (U.S.), among others.
Request Sample Report Here: https://www.meticulousresearch.com/request-sample-report/cp_id=5764
Market Segmentation Insights
The report provides a detailed breakdown of the Middle East IVD market based on various parameters:
- Offerings: The kits and reagents segment is expected to register the highest growth rate due to their extensive use in diagnosing chronic and infectious diseases. This is attributed to the increasing volume of tests for diseases such as HIV and influenza, alongside growing consumer awareness of self-testing options.
- Technologies: Molecular diagnostics, including PCR and next-generation sequencing (NGS), is expected to capture the largest market share in 2024, driven by the rising prevalence of communicable and non-communicable diseases and the need for high-volume, accurate testing.
- Applications: Infectious disease testing is set to dominate the market, with respiratory infections, hepatitis, HIV, and sexually transmitted diseases (STDs) being the primary drivers. The region’s aging population and increasing healthcare demand are also contributing to the rise in testing.
- Diagnostic Approach: Point-of-care testing is expected to exhibit the highest growth, propelled by the increasing burden of chronic diseases and the launch of innovative PoC diagnostics by market leaders.
- End Users: Hospitals and clinics will continue to be the largest segment, performing a wide range of diagnostic tests for various medical conditions, particularly in urban areas where access to healthcare services is more robust.
Country Insights
Among the Middle Eastern countries, Saudi Arabia is projected to dominate the IVD market in 2024, largely due to its rapidly aging population, the high incidence of chronic and infectious diseases, and the growing adoption of self-testing. The Kingdom’s healthcare sector is also experiencing a boost thanks to its Vision 2030 strategy, which aims to elevate healthcare standards and increase investments in medical technologies. Healthcare expenditure in Saudi Arabia is expected to grow annually by 3.0% from 2022 to 2025, further supporting market growth.
Conclusion
The Middle East IVD market presents lucrative opportunities for growth, driven by evolving healthcare needs, technological advancements, and rising awareness around early disease detection. However, market players must navigate challenges related to pricing and diagnostic accuracy to fully capitalize on the region’s potential.
Quick Buy: https://www.meticulousresearch.com/Checkout/69732912
About Meticulous Research®
Meticulous Research® is a globally recognized market research and consulting firm known for delivering in-depth insights across a variety of industries. We provide high-quality market intelligence and strategic guidance to clients across the globe.
Contact Information
Email: sales@meticulousresearch.com
Sales Inquiry: +1-646-781-8004
Connect with us on LinkedIn: Meticulous Research® LinkedIn